SEC Form 4 · accession 0001140361-18-014819

AVADEL PHARMACEUTICALS PLC · AVDL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Mar 22, 2018

Accepted (ET)

Mar 23, 2018 · 4:56 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001012477

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
ADSs^F1,F2	holding	—	—		—	33,100	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5,F1	$7.06	Mar 22, 2018	A	50,000	A	—	Mar 22, 2028	ADSs	50,000	50,000	D
Stock Option (right to buy)^F3,F1	$10.40	holding	—	—	—	—	Dec 14, 2026	ADSs	150,000	150,000	D
Stock Option (right to buy)^F4,F1	$8.95	holding	—	—	—	—	Dec 12, 2027	ADSs	100,000	100,000	D

F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F2Includes 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
F3Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
F4Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
F5Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 3/22/2018 grant date.

Executive VP, Chief Operating Officer